InterACT: Interactions between malaria and HIV drugs in a malaria endemic area
Check out the video
[Project summary in Français / Português]
Scientific title: Interactions between artemisinin-based combination treatment for malaria and antiretrovirals for HIV/AIDS in co-infected patients in Muheza, Tanzania
Latest on this research
More than 17,000 patients were screened for malaria, and about 500 eligible participants were enrolled and successfully completed the study. Scroll down for contact information and for related resources.
What did we know before this research?
In many malaria-endemic countries HIV/AIDS continues to spread, therefore an increasing number of patients need treatment for both infections at the same time.
The World Health Organization and ministries of health in many endemic countries recommend the use of artemisinin-based combination therapy (ACT) for malaria and antiretroviral combination treatments (ART) for HIV/AIDS. Such treatments have become increasingly available.
However, there is cause for concern as some of these drugs share important metabolic cytochrome enzymes. This leads to drug interactions happening in the human body (known as pharmacokinetics) which could make these treatments become toxic and ultimately affect their efficacy.
There is currently very little clinical and pharmacological information available to guide clinicians and policy-makers on the use of drugs for malaria and HIV simultaneously.
What does this study add?
The InterACT project is a study that assesses the clinical safety, therapeutic efficacy and pharmacokinetic interactions between the currently recommended treatment for malaria (a type of ACT called artemether-lumefantrine) and some widely used antiretroviral treatments for HIV/AIDS in Tanzania.
The research team conducted the study among patients with uncomplicated malaria who attend the ‘HIV/AIDS Care and Treatment Clinic’ and ‘Muheza Designated District Hospital’ in Muheza, located in north-eastern Tanzania. This is an area characterized by intense transmission of Plasmodium falciparum malaria and a moderate prevalence of HIV.
The research team
Principal Investigators
- Dr. Lasse Vestergaard, University of Copenhagen
Email: vestergaardl@wpro.who.int
- Dr. Martha Lemnge, Director, National Institute for Medical Research, Tanga Centre, Tanga, Tanzania
- Professor Ib Bygbjerg, Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Other Investigators
- Dr Nyagonde Nyagonde, NIMR, Tanga Centre, Tanzania
- Prof Karen Barnes, University of Cape Town, South Africa
Related Publications
Using rapid diagnostic tests as source of malaria parasite DNA for molecular analyses in the era of declining malaria prevalence
Deus S Ishengoma, Sudi Lwitiho, Rashid A Madebe, Nyagonde Nyagonde, Ola Persson, Lasse S Vestergaard, Ib C Bygbjerg, Martha M Lemnge, Michael Alifrangis | Published
Malaria Journal
Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection
Insaf F. Khalil, Ulla Abildrupa, Lene H. Alifrangis, Deogratius Maigad, Michael Alifrangis, Lotte Hoegberge, Lasse S. Vestergaarda, Ola Per-Eric Perssona, Nyagonde Nyagonded, Martha M. Lemnged, Thor G. Theandera, Ib C. Bygbjerga, | Published
Journal of Pharmaceutical and Biomedical Analysis
Performance of Interferon-Gamma and IP-10 Release Assays for Diagnosing Latent Tuberculosis Infections in Patients with Concurrent Malaria in Tanzania
Camilla H. Drabe, Lasse S. Vestergaard, Marie Helleberg, Nyagonde Nyagonde, Michala V. Rose, Filbert Francis, Ola P. Theilgaard, Jens Asbjrn, Ben Amos, Ib Christian Bygbjerg, Morten Ruhwald and Pernille Ravn | Published
The American Journal of Tropical Medicine and Hygiene